Sigrid Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $5M

  • Investors
  • 16

Sigrid Therapeutics General Information

Description

Operator of a clinical-stage biotechnology company intended to develop a new class of therapies to prevent and treat lifestyle diseases. The company has developed a novel materials platform technology that targets lifestyle diseases by altering the way the body digests food, and the product is the first therapy acting in the gut to improve blood sugar levels in individuals at risk of developing diabetes, helping patients prevent and treat modern-day chronic diseases.

Contact Information

Website
www.sigridthx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Vasagatan 14A
  • 172 61 Sundbyberg
  • Sweden
+46 072-389
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Monitoring Equipment
Vertical(s)
Life Sciences
Corporate Office
  • Vasagatan 14A
  • 172 61 Sundbyberg
  • Sweden
+46 072-389

Sigrid Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sigrid Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 07-Jan-2026 $5M Completed Generating Revenue
12. Later Stage VC 31-Oct-2023 Completed Clinical Trials - General
11. Later Stage VC 16-Jan-2023 Completed Clinical Trials - General
10. Later Stage VC 09-Nov-2021 Completed Clinical Trials - General
9. Grant 25-Mar-2020 Completed Clinical Trials - General
8. Early Stage VC 20-Aug-2019 Completed Clinical Trials - General
7. Grant 28-May-2019 Completed Clinical Trials - General
6. Accelerator/Incubator Completed Generating Revenue
5. Accelerator/Incubator 14-Sep-2018 $6.62M Completed Clinical Trials - General
4. Early Stage VC 27-Aug-2018 $4.49M $6.62M Completed Clinical Trials - General
To view Sigrid Therapeutics’s complete valuation and funding history, request access »

Sigrid Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 42,481 $13.79 $13.79 1x $13.79 5.85%
Ordinary 77,099 $12.37 $12.37 1x $12.37 10.61%
To view Sigrid Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Sigrid Therapeutics Patents

  • 40

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

Sigrid Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4757768-A1 Chewable composition comprising porous silica particles Pending 09-Aug-2023
WO-2025032243-A1 Chewable composition comprising porous silica particles Inactive 09-Aug-2023
GB-202312179-D0 New compositions and uses Inactive 09-Aug-2023
GB-202312176-D0 New uses and methods Inactive 09-Aug-2023
EP-4757818-A1 Use of compositions comprising porous silica in preventing or inhibiting bacterial growth Pending 09-Aug-2023 A61K33/00
To view Sigrid Therapeutics’s complete patent history, request access »

Sigrid Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sigrid Therapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alsteron Family Office Minority
Angel (individual) Minority
Axilium Holding Venture Capital Minority
Crosslight Partners Growth/Expansion Minority
Irrus Investments Angel Group Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

Sigrid Therapeutics FAQs

  • When was Sigrid Therapeutics founded?

    Sigrid Therapeutics was founded in 2014.

  • Where is Sigrid Therapeutics headquartered?

    Sigrid Therapeutics is headquartered in Sundbyberg, Sweden.

  • What is the size of Sigrid Therapeutics?

    Sigrid Therapeutics has 17 total employees.

  • What industry is Sigrid Therapeutics in?

    Sigrid Therapeutics’s primary industry is Therapeutic Devices.

  • Is Sigrid Therapeutics a private or public company?

    Sigrid Therapeutics is a Private company.

  • What is Sigrid Therapeutics’s current revenue?

    The current revenue for Sigrid Therapeutics is .

  • How much funding has Sigrid Therapeutics raised over time?

    Sigrid Therapeutics has raised $26.6M.

  • Who are Sigrid Therapeutics’s investors?

    Alsteron, , Axilium Holding, Crosslight Partners, and Irrus Investments are 5 of 16 investors who have invested in Sigrid Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process